文献速递心力衰竭与心肌病

非奈利酮治疗射血分数轻度降低或保留的心力衰竭中血钾与临床结局

Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction.
PubMed 文献 · JAMA Cardiol · 2025-01-01

该研究为FINEARTS-HF试验的二次分析,纳入6001例射血分数≥40%的心力衰竭患者,评估非奈利酮对血钾的影响及基于随机后血钾的疗效。非奈利酮增加高钾血症风险(HR 2.16)并降低低钾血症风险(HR 0.46),但即使血钾升至>5.5 mmol/L,其临床获益仍维持。

要点

  • 非奈利酮增加高钾血症风险,但降低低钾血症风险。
  • 高钾和低钾均与主要结局风险升高相关。
  • 在方案指导监测和剂量调整下,非奈利酮获益持续。

核心结论

  • 非奈利酮导致高钾血症更频繁、低钾血症更少,但在方案指导监测和剂量调整下,即使血钾升至>5.5 mmol/L,临床获益仍维持。

研究设计与样本

  • FINEARTS-HF多中心随机临床试验的二次分析,纳入6001例射血分数≥40%、NYHA II-IV级、利钠肽升高的心衰患者,中位随访32个月。

主要发现

  • 非奈利酮组1个月血钾中位差值较安慰剂组高0.19 mmol/L,3个月高0.23 mmol/L,并持续至随访结束。
  • 低钾(<3.5 mmol/L;HR 2.49,95%CI 1.8-3.43)和高钾(>5.5 mmol/L;HR 1.64,95%CI 1.04-2.58)均与主要结局风险升高相关。
  • 即使血钾升至>5.5 mmol/L,非奈利酮组主要结局风险仍普遍低于安慰剂组。

关键数值与推荐

  • 高钾血症定义为血钾>5.5 mmol/L,低钾血症定义为血钾<3.5 mmol/L。
  • 主要结局为总心力衰竭恶化事件或心血管死亡的复合终点。

临床怎么用

  • 使用非奈利酮时应按方案监测血钾并调整剂量,以维持临床获益。

局限性

  • 本研究为FINEARTS-HF试验的二次分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), improved outcomes in patients with heart failure with mildly reduced or preserved ejection fraction in FINEARTS-HF, but was associated with increased levels of serum potassium in follow-up. OBJECTIVE: To investigate the frequency and predictors of serum potassium level greater than 5.5 mmol/L and less than 3.5 mmol/L and examine the treatment effect associated with finerenone, relative to placebo, on clinical outcomes based on postrandomization potassium levels. DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of the FINEARTS-HF multicenter, randomized clinical trial, performed between September 14, 2020, and January 10, 2023, with a median follow-up of 32 months (final date of follow-up: June 14, 2024). Patients with heart failure and left ventricular ejection fraction greater than or equal to 40%, New York Heart Association class II to IV symptoms, and elevated natriuretic peptides were included. INTERVENTION: Participants received finerenone or placebo. MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of total worsening heart failure events or cardiovascular death. RESULTS: A total of 6001 participants were included (3003 randomized to receive finerenone and 2998 randomized to receive placebo). The increase in serum potassium was greater in the finerenone group than the placebo group at 1 month (median [IQR] difference, 0.19 [0.17-0.21] mmol/L) and 3 months (median [IQR] difference, 0.23 [0.21-0.25] mmol/L), which persisted for the remainder of trial follow-up. Finerenone increased the risks of potassium level increasing to greater than 5.5 mmol/L (hazard ratio [HR], 2.16 [95% CI, 1.83-2.56]; P < .001) and decreased the risks for potassium level decreasing to less than 3.5 mmol/L (HR, 0.46 [95% CI, 0.38-0.56]; P < .001). Both low (< 3.5 mmol/L; HR, 2.49 [95% CI, 1.8-3.43]) and high (>5.5 mmol/L; HR, 1.64 [95% CI, 1.04-2.58]) potassium levels were associated with higher subsequent risks of the primary outcome in both treatment groups. Nevertheless, the risk of the primary outcome was generally lower in patients treated with finerenone compared with placebo, even in those whose potassium level increased to greater than 5.5 mmol/L. CONCLUSIONS AND RELEVANCE: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone resulted in more frequent hyperkalemia and less frequent hypokalemia. However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.

来源:JAMA Cardiol,查看原文。版权归原作者所有。

引用

  1. Vardeny, Vaduganathan, Claggett, et al. Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. JAMA Cardiol. 2025. PMID: 39550716. doi:10.1001/jamacardio.2024.4539

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。